1)日本動脈硬化学会,編.動脈硬化性疾患予防ガイドライン2012年版.日本動脈硬化学会,2012
|
|
|
2)Dawber TR, Meadors GF, Moore FE Jr. Epidemiological approaches to heart disease: the Framingham Study. Am J Public Health Nations Health. 1951; 41: 279-81
|
|
|
3)Kannel WB, Dawber TR, Friedman GD, et al. Risk factors in coronary heart disease. an evaluation of several serum lipids as predictors of coronary heart disease; the Framingham study. Ann Intern Med. 1964; 61: 888-9
|
|
|
4)Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977; 62: 707-14
|
|
|
5)Kannel WB. Lipids, diabetes, and coronary heart disease: insights from the Framingham Study. Am Heart J. 1985; 110: 1100-7
|
|
|
6)Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972; 18: 499-502
|
|
|
7)Miller WG, Myers GL, Sakurabayashi I, et al. Seven direct methods for measuring HDL and LDL cholesterol compared with ultracentrifugation reference measurement procedures. Clin Chem. 2010; 56: 977-86
|
|
|
8)Miida T, Nishimura K, Okamura T, et al. A multicenter study on the precision and accuracy of homogeneous assays for LDL-cholesterol: comparison with a beta-quantification method using fresh serum obtained from non-diseased and diseased subjects. Atherosclerosis. 2012; 225: 208-15
|
|
|
9)Kurosawa H, Yoshida H, Yanai H, et al. Comparative study between anion-exchange HPLC and homogeneous assay methods in regard to the accuracy of high- and low-density lipoprotein cholesterol measurement. Clin Biochem. 2007; 40: 1291-6
|
|
|
10)Miller WG, Waymack PP, Anderson FP, et al. Performance of four homogeneous direct methods for LDL-cholesterol. Clin Chem. 2002; 48: 489-98
|
|
|
11)Ishikawa T, Mizuno K, Nakaya N, et al; MEGA Study Group. The relationship between the effect of pravastatin and risk factors for coronary heart disease in Japanese patients with hypercholesterolemia. Circ J. 2008; 72: 1576-82
|
|
|
12)Saito Y, Yokoyama M, Origasa H, et al; JELIS Investigators. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis. 2008; 200: 135-40
|
|
|
13)Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996; 3: 213-9
|
|
|
14)Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation. 2007; 115: 450-8
|
|
|
15)Leary ET, Wang T, Baker DJ, et al. Evaluation of an immunoseparation method for quantitative measurement of remnant-like particle-cholesterol in serum and plasma. Clin Chem. 1998; 44: 2490-8
|
|
|
16)Kugiyama K, Doi H, Takazoe K, et al. Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease. Circulation. 1999; 99: 2858-60
|
|
|
17)Nakamura T, Obata JE, Hirano M, et al. Predictive value of remnant lipoprotein for cardiovascular events in patients with coronary artery disease after achievement of LDL-cholesterol goals. Atherosclerosis. 2011; 218: 163-7
|
|
|
18)Miyauchi K, Kayahara N, Ishigami M, et al. Development of a homogeneous assay to measure remnant lipoprotein cholesterol. Clin Chem. 2007; 53: 2128-35
|
|
|
19)Okamura T, Kokubo Y, Watanabe M, et al. Triglycerides and non-high-density lipoprotein cholesterol and the incidence of cardiovascular disease in an urban Japanese cohort: the Suita study. Atherosclerosis. 2010; 209: 290-4
|
|
|
20)Boekholdt SM, Arsenault BJ, Mora S, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA. 2012; 307: 1302-9
|
|
|
21)真仁田大輔,吉田 博.イオン交換クロマトグラフィによるリポ蛋白分析法の開発と臨床的有用性.細胞. 2015; 47: 348-51
|
|
|
22)吉田 博.HPLCリポ蛋白定量法の臨床的有用性.臨床病理.2010; 58: 1093-8
|
|
|
23)Ito K, Yoshida H, Yanai H, et al. Relevance of intermediate-density lipoprotein cholesterol to Framingham risk score of coronary heart disease in middle-aged men with increased non-HDL cholesterol. Int J Cardiol. 2013; 168: 3853-8
|
|
|
24)Movva R, Rader DJ. Laboratory assessment of HDL heterogeneity and function. Clin Chem. 2008; 54: 788-800
|
|
|
25)Boekholdt SM, Arsenault BJ, Mora S, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA. 2012; 307: 1302-9
|
|
|
26)Thanassoulis G, Williams K, Ye K, et al. Relations of change in plasma levels of LDL-C, non-HDL-C and apoB with risk reduction from statin therapy: a meta-analysis of randomized trials. J Am Heart Assoc. 2014; 3: e000759
|
|
|
27)McQueen MJ, Hawken S, Wang X, et al; INTERHEART study investigators. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet. 2008; 372: 224-33
|
|
|
28)Ndumele CE, Matsushita K, Astor B, et al. Apo-lipoproteins do not add prognostic information beyond lipoprotein cholesterol measures among individuals with obesity and insulin resistance syndromes: the ARIC study. Eur J Prev Cardiol. 2014; 21: 866-75
|
|
|
29)Masuda D, Nishida M, Arai T, et al. Reference interval for the apolipoprotein B-48 concentration in healthy Japanese individuals. J Atheroscler Thromb. 2014; 21: 618-27
|
|
|
30)増田大作.家族性III型高脂血症の病因と臨床における意義.Pharma Medica. 2015; 33: 29-33
|
|
|
31)Qamar A, Khetarpal SA, Khera AV, et al. Plasma apolipoprotein C-III levels, triglycerides, and coronary artery calcification in Type 2 diabetics. Arterioscler Thromb Vasc Biol. 2015; 35: 1880-8
|
|
|
32)Bernelot Moens SJ, van Capelleveen JC, Stroes ES. Inhibition of ApoCIII: the next PCSK9? Curr Opin Lipidol. 2014; 25: 418-22
|
|
|
33)Steinberg D, Witztum JL. Oxidized low-density lipoprotein and atherosclerosis. Arterioscler Thromb Vasc Biol. 2010; 30: 2311-6
|
|
|
34)Yoshida H, Quehenberger O, Kondratenko N, et al. Minimally oxidized low-density lipoprotein increases expression of scavenger receptor A, CD36, and macrosialin in resident mouse peritoneal macrophages. Arterioscler Thromb Vasc Biol. 1998; 18: 794-802
|
|
|
35)吉田 博.酸化リポ蛋白の最前線.臨床病理.2010; 58: 622-30
|
|
|
36)Naruko T, Ueda M, Ehara S, et al. Persistent high levels of plasma oxidized low-density lipoprotein after acute myocardial infarction predict stent restenosis. Arterioscler Thromb Vasc Biol. 2006; 26: 877-83
|
|
|
37)吉田 博.酸化LDL測定の臨床的有用性.医学のあゆみ.2008; 227: 1087-9
|
|
|
38)Yoshida H, Ishikawa T, Nakamura H. Vitamin E/lipid peroxide ratio and susceptibility of LDL to oxidative modification in non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol. 1997; 17: 1438-46
|
|
|
39)Tanaga K, Bujo H, Inoue M, et al. Increased circulating malondialdehyde-modified LDL levels in patients with coronary artery diseases and their association with peak sizes of LDL particles. Arterioscler Thromb Vasc Biol. 2002; 22: 662-6
|
|
|
40)Hiki M, Shimada K, Ohmura H, et al. Serum levels of remnant lipoprotein cholesterol and oxidized low-density lipoprotein in patients with coronary artery disease. J Cardiol. 2009; 53: 108-16
|
|
|
41)Salonen JT, Yla-Herttuala S, Yamamoto R, et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet. 1992; 339: 883-7
|
|
|
42)Torzewski M, Shaw PX, Han KR, et al. Reduced in vivo aortic uptake of radiolabeled oxidation-specific antibodies reflects changes in plaque composition consistent with plaque stabilization. Arterioscler Thromb Vasc Biol. 2004; 24: 2307-12
|
|
|
43)Palinski W, Witztum JL. Immune responses to oxidative neoepitopes on LDL and phospholipids modulate the development of atherosclerosis. J Intern Med. 2000; 247: 371-80
|
|
|
44)吉田 博.古くて新しい動脈硬化リスク因子Lp(a).臨床化学.2015; 44: 152-3
|
|
|
45)Bennet A, Di Angelantonio E, Erqou S, et al. Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data. Arch Intern Med. 2008; 168: 598-608
|
|
|
46)Emerging Risk Factors Collaboration, Erqou S, Kaptoge S, Perry PL, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009; 302: 412-23
|
|
|
47)Kronenberg F, Kronenberg MF, Kiechl S, et al. Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck study. Circulation. 1999; 100: 1154-60
|
|
|
48)吉田 博.リポ蛋白(a)は動脈硬化性疾患の多面的危険因子.冠動脈疾患のパーフェクトマネジメント.In: 伊藤 浩,編.東京: 南江堂; 2014. p.92-7
|
|
|
49)Tsimikas S, Brilakis ES, Miller ER, et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med. 2005; 353: 46-57
|
|
|
50)Tsimikas S, Kiechl S, Willeit J, et al. Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: five-year prospective results from the Bruneck study. J Am Coll Cardiol. 2006; 47: 2219-28
|
|
|
51)Tsimikas S, Witztum JL. The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity. Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: five-year prospective results from the Bruneck study. Curr Opin Lipidol. 2008; 19: 369-77
|
|
|
52)Bergmark C, Dewan A, Orsoni A, et al. A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma. J Lipid Res. 2008; 49: 2230-9
|
|
|
53)Lp-PLA(2) Studies Collaboration, Thompson A, Gao P, Orfei L, et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet. 2010; 375: 1536-44
|
|
|
54)Hung MY, Witztum JL, Tsimikas S. New therapeutic targets for calcific aortic valve stenosis: the lipoprotein(a)-lipoprotein-associated phospholipase A2-oxidized phospholipid axis. J Am Coll Cardiol. 2014; 63: 478-80
|
|
|
55)久松隆史,上島弘嗣,三浦克之.Lp-PLA2.動脈硬化予防.2015; 14: 113-8
|
|
|
56)Yeboah J, McClelland RL, Polonsky TS, et al. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA. 2012; 308: 788-95
|
|
|
57)Tsimikas S, Willeit P, Willeit J, et al. Oxidation-specific biomarkers, prospective 15-year cardiovascular and stroke outcomes, and net reclassification of cardiovascular events. J Am Coll Cardiol. 2012; 60: 2218-29
|
|
|
58)Rohatgi A, Khera A, Berry JD, et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med. 2014; 371: 2383-93
|
|
|